What's new

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised

May 2, 2025 - 15:12
 0
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised
Human medicines European public assessment report (EPAR): Beyfortus, nirsevimab, Date of authorisation: 31/10/2022, Revision: 12, Status: Authorised
Read More

Tags:

Previous Article

AlUla and the New 7,000-Year-Old Tourist Destination – Skift Travel Podcast

Next Article

Human medicines European public assessment report (EPAR): Bekemv, eculizumab, Da...

Related Posts

Human medicines European public assessment report (EPAR): Segluromet, ertugliflozin,metformin hydrochloride, Date of authorisation: 23/03/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR...

May 2, 2025  0

Summary of opinion: Vyvgart, 25/04/2025 Positive

Summary of opinion: Vyvgart, 25/04/2025 Positive

Apr 25, 2025  0

Human medicines European public assessment report (EPAR): Pritor, telmisartan, Date of authorisation: 11/12/1998, Revision: 31, Status: Authorised

Human medicines European public assessment report (EPAR...

Apr 23, 2025  0